Dobutamine Hydrochloride Injection

1. It has a positive inotropic effect on the myocardium, mainly acting on beta-1 receptors, and has a relatively small effect on beta-2 and alpha receptors; 2. It can directly excite cardiac beta-1 receptors to enhance myocardial contraction and increase stroke volume, thereby increasing cardiac output; 3. It can reduce peripheral vascular resistance (reduced afterload), but systolic blood pressure and pulse pressure generally remain unchanged, or only increase due to increased cardiac output; 4. It can reduce ventricular filling pressure and promote atrioventricular node conduction; 5. Myocardial contractility is enhanced, and coronary blood flow and myocardial oxygen consumption often increase; 6. Due to increased cardiac output, renal blood flow and urine volume often increase; 7. Unlike dopamine, dobutamine does not act indirectly through the release of endogenous norepinephrine, but directly on the heart.

The main ingredients and chemical name of this product are: 4-[２-[[１-methyl-3-(4-hydroxyphenyl)propyl]amino]ethyl]-1,2-benzenediol hydrochloride. Molecular formula: C18H23NO3HCl Molecular weight: 337.85

This product is a colorless clear liquid.

It is used as a short-term supportive treatment for heart failure caused by decreased myocardial contractility in patients with organic heart disease, including low output syndrome caused by open heart surgery.

The commonly used dose for adults is dobutamine diluted in 5% glucose solution or 0.9% sodium chloride injection, and then given at a drip rate of 2.5-10ug/kg per minute. At doses below 15ug/kg per minute, heart rate and peripheral vascular resistance remain basically unchanged; occasionally >15ug/kg per minute is used, but it should be noted that excessive doses may still accelerate the heart rate and produce arrhythmias.

There may be palpitations, nausea, headache, chest pain, shortness of breath, etc. If systolic blood pressure increases (mostly by 1.33-2.67Kpa (10-20mmHg), a few by 6.67Kpa (50mmHg) or more), heart rate increases (mostly by 5-10 beats per minute, a few by more than 30 beats per minute), it is related to the dosage and the dosage should be reduced or the medication should be suspended.

1. When used together with general anesthetics, especially cyclopropane and halothane, the possibility of ventricular arrhythmias increases; 2. When used together with beta-receptor blockers, it can antagonize the effect of this product on beta-1 receptors, resulting in the dominance of alpha-receptor effects and increased total peripheral vascular resistance; 3. When used together with sodium nitroprusside, it can lead to a slight increase in cardiac output and a slight decrease in pulmonary wedge pressure; 4. This product must not be mixed with alkaline drugs such as sodium bicarbonate.

Keep away from light and store in a sealed container.

2ml:20mg (calculated as C18H23NO3)

Avanc Pharmaceutical Co., Ltd.

• Founded in:

  2002-01-28

• Address:

  No. 55, Songshan Street, Taihe District, Jinzhou City, Liaoning Province

• Tax NO.:

  91210700734224812X

• Registered Funds:

  660 million yuan

• Website:

  Log in to view

• Email:

  Log in to view